Insight Molecular Diagnostics says study shows GraftAssure CM-Score lifts kidney transplant rejection PPV to 81%

• Insight Molecular Diagnostics announced an American Journal of Transplantation pre-proof supporting its GraftAssure kidney transplant rejection monitoring assay.
• Results were first presented as a late-breaking report at the World Transplant Congress in August 2025.
• The analysis found a combined-score approach outperformed single-measure dd-cfDNA methods, improving rule-in confidence while maintaining strong rule-out performance.
• The dataset included both screening and for-cause testing cohorts, with validation against multiple published cohorts.
• Management plans to present the findings at the American Transplant Congress on June 20-24, 2026, as it pursues FDA authorization for test kits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606111617PRIMZONEFULLFEED9745830) on June 11, 2026, and is solely responsible for the information contained therein.